v3.25.2
SEGMENT REPORTING
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
SEGMENT REPORTING SEGMENT REPORTING
The Company manages business activities on an aggregated basis and operates in one reportable segment: therapeutics. The therapeutics segment derives revenue primarily through sales of XDEMVY to specialty pharmacies and distributors in the U.S., who in turn sell it directly to clinics, hospitals, pharmacies and federal healthcare programs. The segment also generates license fees and collaboration revenue related to the China Out-License (see Note 9). The accounting policies of the therapeutics segment are the same as those described in the summary of significant accounting policies (see Note 2).
The Company’s chief operating decision-maker ("CODM") is its Chief Executive Officer ("CEO"). The CODM uses net loss, as reported in the accompanying Condensed Statements of Operations and Comprehensive Loss, to assess performance of the therapeutics segment and in deciding whether to allocate resources into the therapeutics segment or outside the segment, such as for acquisitions or new in-license agreements. The CODM uses net loss to regularly monitor budget versus actual results which are used in assessing performance of the segment and in establishing management’s compensation. The
CODM does not review assets in evaluating the results of the therapeutics segment, and therefore, such information is not presented.
The following table provides the operating financial results of the therapeutics segment:
 Three Months Ended June 30,Six Months Ended June 30,
 2025202420252024
Revenues:
Product sales, net$102,660 $40,813 $180,995 $65,533 
License fees and collaboration revenue— — — 2,894 
Total revenues102,660 40,813 180,995 68,427 
Operating expenses:
Cost of sales6,237 3,004 11,448 4,658 
Research and development15,594 12,319 30,003 24,385 
Selling and marketing65,857 32,251 126,143 60,138 
General and administrative37,156 26,541 61,865 50,232 
Total operating expenses124,844 74,115 229,459 139,413 
Loss from operations(22,184)(33,302)(48,464)(70,986)
Other reconciling items(1)
1,844 12 3,004 1,965 
Net loss$(20,340)$(33,290)$(45,460)$(69,021)
Other segment disclosures:
Interest income$4,229 $4,130 $7,683 $7,247 
Interest expense$(2,240)$(2,109)$(4,453)$(3,092)
Depreciation and amortization expense$453 $239 $913 $509 
(1) Other reconciling items primarily includes interest income and interest expense. In the prior year periods, other reconciling items also included loss on debt extinguishment.